A Critical Appraisal of Non-Invasive Technologies in NASH
Informing the Future of NASH Diagnosis and Assessment
Clinical Practice Guidelines
American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD).
Cusi K, Isaacs S, Barb D, et al. Endocr Pract. 2022;28(5):528-562.
Clinical Resources
NAFLD (Non-Alcoholic Fatty Liver Disease) fibrosis score.
Fibrosis-4 (FIB-4) index for liver fibrosis.
AST to platelet ratio index (APRI).
Suggested Readings
Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials.
Anstee QM, Lawitz EJ, Alkhouri N, et al. Hepatology. 2019;70(5):1521-1530.
Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action.
Bril F, Cusi K. Diabetes Care. 2017;40(3):419-430.
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.
Dulai PS, Singh S, Patel J, et al. Hepatology. 2017;65(5):1557-1565.
Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease.
Eddowes PJ, Sasso M, Allison M, et al. Gastroenterology. 2019;156(6):1717-1730.
Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening.
Lomonaco R, Godinez Leiva E, Bril F, et al. Diabetes Care. 2021;44(2):399-406.
Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States Is cost-effective: a comprehensive cost-utility analysis.
Noureddin M, Jones C, Alkhouri N, et al. Gastroenterology. 2020;159(5):1985-1987.e1984.
Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease.
Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Clin Gastroenterol Hepatol. 2019;17(1):156-163.e152.
Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.
Srivastava A, Gailer R, Tanwar S, et al. J Hepatol. 2019;71(2):371-378.
Update on NAFLD genetics: from new variants to the clinic.
Trépo E, Valenti L. J Hepatol. 2020;72(6):1196-1209.
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis.
Younossi ZM, Golabi P, de Avila L, et al. J Hepatol. 2019;71(4):793-801.
Performance of the enhanced liver fibrosis test to estimate advanced fibrosis among patients with nonalcoholic fatty liver disease.
Younossi ZM, Felix S, Jeffers T, et al. JAMA Netw Open. 2021;4(9):e2123923.
Role of noninvasive tests in clinical gastroenterology practices to identify patients with nonalcoholic steatohepatitis at high risk of adverse outcomes: expert panel recommendations.
Younossi ZM, Noureddin M, Bernstein D, et al. Am J Gastroenterol. 2021;116(2):254-262.
Relevant Resources
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
An Interactive Learning Experience
A Focus on Clinical Evidence and Guideline Recommendations
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
A Multidisciplinary Look at Early Diagnosis and Management
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
An Updated Clinician’s Guide to Assessment and Management
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
A Multidisciplinary Approach
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
A Phone-a-Friend CME Series – Volume 2
Incorporating New Data and Updated Guidelines Into Daily Practice
Exercising Best Practices for Hospitalized Patients
